Results. A total of 6,055 resistant and 50,302 susceptible infections were identified; 2,800 and 16,585, respectively, received DAT. In multivariate analyses, DAT was associated with worse outcomes, including a 20% increased risk of composite mortality and an approximate 70% increase in LOS and total costs, respectively.
Assessment of risk factors for inappropriate empiric antibiotic therapy in patients with
Background. The association between the administration of inappropriate empiric antibiotic treatment (IEA) and an increased risk of hospital mortality has been consistently reported. This study explores pre-infection risk factors for IEA in patients with Gram-negative (GN) sterile site infections complicated by sepsis or septic shock.
Methods. Retrospective cohort study at Barnes-Jewish Hospital (2010 -2015 . Risk factors including history of hospitalization, receipt of intravenous antipseudomonal antibiotics, and isolation of GN organisms 90 days prior to admission were collected. Process of care variables assessed included ICU admission, durations of mechanical ventilation, central venous catheter, and urinary catheter insertion, and antibiotic days prior to isolation of a GN pathogen(s). IEA was defined as receipt of antibiotic therapy that lacked in vitro activity against the identified pathogen(s) within the 24 hours of the culture being obtained. Multivariable logistic regression analysis (MVLRA) risk factor modeling that included IEA as the dependent outcome variable was conducted.
Results. 855 consecutive patients with first episode sepsis or septic shock were included. Compared with patients receiving appropriate empiric therapy (n = 715), variables significantly associated with IEA (n = 140) within 90 days prior to admission included recent hospitalization (23.1% v. 34.3%, P = 0.005), mean days of meropenem (0 v. 2.1, P = 0.010) and piperacillin-tazobactam (0 v. 1.6, P <0.001) therapy, and isolation of a GN organism(s) (8.4% v. 20.0%, P <0.001). Prior to isolation of the GN pathogen(s), median hospital (0 v. 6 days, P < 0.001) and ICU (0 v. 0 days, P < 0.001) length of stay, as well as the median duration of CVC dwell time (10 v. 17 days, P = 0.050) was associated with IEA. MVLRA identified isolation of a GN pathogen (AOR 3.432 95% CI 2.024-5.820, P <0.001) and days of piperacillin-tazobactam therapy (AOR 1.149 95% CI 1.061-1.245, P <0.001) in the 90 days prior to admission, as well as Charlson score (AOR 1.097 95% CI 1.023-1.177, p + 0.010) as independent risk factors for IEA.
Conclusion. Consideration of risk factors prior to admission and prior to collection of a sterile site specimen appear to be critical when making empiric antibiotic decisions targeting GN pathogens in patients with sepsis or septic shock.
Disclosures. S. Micek, Merck: Grant Investigator, Research grant. Background. The quality of antibiotics is a crucial element in successful treatment of infections. Recently, the use of generic antibiotics has caused controversy because of studies reporting clinical failure and the emergence of antibacterial resistance associated with the sustained use of generic antibiotics. The present study was designed to determine the mortality associated with the use of generic meropenem (GM) and brand-name meropenem (BNM) used to treat Gram-negative infections.
Effect of Generic vs. Brand-Name Meropenem on Mortality in a Colombian
Methods. We conducted an ambispective cohort study comparing adult patients who received GM and BNM while in the intensive care unit of a tertiary care hospital in Colombia. Patients treated between January 2011 and May 2014 received GM while patients treated between June 2014 and March 2017 received BNM. Patients were included in the study only if the infecting organism was susceptible to meropenem. The GM and BNM cohorts were paired by age, infection type, and infection severity as measured by Sequential Organ Failure Assessment score. Mortality was compared between groups. Data were analyzed using descriptive and inferential statistics.
Results. A total of 168 patients were included; 68 patients (40%) were treated with GM and 100 (60%) were treated with BNM. The mean age was 57 years old; 72 (43%) women and 96 (57%) men. The most common infecting organism was E. coli (35%) followed by K. pneumoniae (19%). Bacteremia (49%) was the most common infection type, followed by intraabdominal infection (24%). Multivariate analysis demonstrated that patients treated with GM had a risk of death 18 times higher (OR: 18.45 95% CI 1.47-232, P = 0.024) than patients treated with BNM. Patients with a history of cardiovascular disease had an independent risk of death compared with those without cardiovascular disease. Other comorbidities and time between bacterial culture and initiation of treatment with meropenem did not have a statistically significant effect on mortality.
Conclusion. The present study suggests that patients treated with GM have worse clinical outcomes compared with those treated with BNM. More studies are needed to confirm the clinical superiority of brand-name vs. generic antibiotics, not only for meropenem but also for other commonly-used molecules. 
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